(19)
(11) EP 4 157 454 A2

(12)

(88) Date of publication A3:
03.02.2022

(43) Date of publication:
05.04.2023 Bulletin 2023/14

(21) Application number: 21817223.7

(22) Date of filing: 02.06.2021
(51) International Patent Classification (IPC): 
A61P 29/00(2006.01)
A61P 37/04(2006.01)
 A61P 19/02(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 45/06; A61K 31/192; A61K 31/235; Y02A 50/30
 
C-Sets:
  1. A61K 31/192, A61K 2300/00;
  2. A61K 31/235, A61K 2300/00;
(86) International application number:
PCT/US2021/035395
(87) International publication number:
WO 2021/247665 (09.12.2021 Gazette 2021/49)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(30) Priority: 02.06.2020 US 202016891034

(71) Applicants:
  • Mufarrij, Imad
    Bowie, MD 207163969 (US)
  • Antakly, Tony
    Potomac, MD 20854 (US)

(72) Inventor:
  • ANTAKLY, Tony
    Potomac, MD 20854 (US)

(74) Representative: Potter Clarkson 
Chapel Quarter Chapel Bar
Nottingham NG1 6HQ
Nottingham NG1 6HQ (GB)

   


(54) PPAR-GAMMA ACTIVATORS, HDAC INHIBITORS AND THEIR THERAPEUTICAL USAGES